Login to Your Account



Clinic Roundup


Thursday, May 5, 2011
SARcode Corp., of Brisbane, Calif., presented data for its lead investigational molecule, SAR 1118. In a Phase II dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production and improved visual-related function as compared to placebo. The data were part of the scientific program of the Association for Research in Vision and Ophthalmology Annual Meeting held in Fort Lauderdale, Fla.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription